SCHEMBL2401022

SCHEMBL2401022

C=C(C)Cc1ccc(C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
KMT2A Q03164 5/20 0.53
RARB P10826 6/20 0.50
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
RARA P10276 1/20 0.47
MTOR P42345 1/20 0.47
SRD5A2 P31213 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
THRB P10828 1/20 0.47
NR4A1 P22736 1/20 0.47
APEX1 P27695 1/20 0.47
APOBEC3A P31941 1/20 0.47
RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9635304 0.94 RARB (0.59) ALDH1A1KMT2ARARBMEN1MAPT
SCHEMBL49090 0.83 ALDH1A1 (0.61) ALDH1A1KMT2ARARBTP53TSHR
Benzoic Acid SCHEMBL31606729 0.82 TP53 (0.56) ALDH1A1TP53MAPTSMN1; SMN2USP2
SCHEMBL10455113 0.82 KMT2A (0.42) ALDH1A1KMT2AMAPTSMN1; SMN2POLB
SCHEMBL6015468 0.82 ALDH1A1 (0.38) ALDH1A1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL28170706 0.81 ALDH1A1 (0.59) ALDH1A1KMT2ARARBTP53TSHR
SCHEMBL11300567 0.80 KMT2A (0.38) ALDH1A1KMT2ASMN1; SMN2KDM4EPOLB
SCHEMBL14495580 0.80 POLB (0.52) ALDH1A1KMT2ATSHRPOLBGAA
SCHEMBL2000488 0.80 RARB (0.56) ALDH1A1KMT2ARARBTP53TSHR
Terephthalic Acid SCHEMBL1929898 0.79 TSHR (0.71) ALDH1A1KMT2ATP53TSHRSRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025041533-A1 SEMICONDUCTOR SUBSTRATE PRODUCTION METHOD AND FILM-FORMING COMPOSITION JSR株式会社 2025-02-27 WO disclosed
CN-110684350-A Electrical equipment shell material for hydrogen explosion-proof environment 张家港氢芯电气系统科技有限公司 2020-01-14 CN disclosed
EP-1953239-B1 METHOD FOR DETERMINATION OF ALLERGEN IN ENVIRONMENT AND KIT FOR SIMPLE QUANTIFICATION OF ALLERGEN JAPAN SCIENCE & TECH AGENCY (JP) 2012-10-17 EP disclosed
US-8012708-B2 Method for determination of allergen in environment and kit for simple quantification of allergen JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-06 US disclosed
US-20090215814-A1 Method of inhibiting neurotrophin-receptor binding QUEEN'S UNIVERSITY AT KINGSTON (CA) 2009-08-27 US disclosed
US-20090203058-A1 Method for determination of allergen in environment and kit for simple quantification of allergen JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2009-08-13 US disclosed
US-7541368-B2 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) AVENTIS PHARMACEUTICALS INC. (US) 2009-06-02 US disclosed
WO-2008120811-A1 ORGANIC - INORGANIC HYBRID COMPOSITION FUJIFILM CORPORATION (JP) 2008-10-09 WO disclosed
EP-1953239-A1 METHOD FOR DETERMINATION OF ALLERGEN IN ENVIRONMENT AND KIT FOR SIMPLE QUANTIFICATION OF ALLERGEN Japan Science and Technology Agency (JP) 2008-08-06 EP disclosed
US-20080050764-A1 Method and Apparatus for Measuring Enviromental Allergen JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2008-02-28 US disclosed
WO-2008014221-A2 BRIDGED CARBAMATE MACROLIDES ENANTA PHARMACEUTICALS, INC. (US) 2008-01-31 WO disclosed
EP-1622610-B1 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AVENTIS PHARMA INC (US) 2006-12-20 EP disclosed
EP-1712637-A1 METHOD AND APPARATUS FOR MEASURING ENVIRONMENTAL ALLERGEN Japan Science and Technology Agency (JP) 2006-10-18 EP disclosed
US-20060063796-A1 Pyrazoles as inhibitors of tumor necrosis factor AVENTIS PHARMACEUTICALS INC. (US) 2006-03-23 US disclosed
EP-1622610-A1 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS Aventis Pharmaceuticals Inc. (US) 2006-02-08 EP disclosed
WO-2004100946-A1 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS AVENTIS PHARMACEUTICALS INC. (US) 2004-11-25 WO disclosed
EP-0283326-B1 LIQUID CRYSTAL COMPOUNDS WITH 4-(OPTICALLY ACTIVE ALKYL)-3-CYANOPHENYL GROUPS Chisso Corporation (JP) 1992-06-24 EP disclosed
US-4913838-A LARGE SPONTANEOUS POLARIZATION VALUE CHISSO CORPORATION (JP) 1990-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215814-A1 Method of inhibiting neurotrophin-receptor binding NGF, NTRK2, BDNF ALDH1A1 2096/4885KMT2A 3466/4885RARB 2710/4885
US-20060063796-A1 Pyrazoles as inhibitors of tumor necrosis factor TNF, LITAF, MAPK1 ALDH1A1 1448/4885KMT2A 4746/4885RARB 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.